Posts in: NCT

Pharma Manufacturing: EXOZ selects Curia
press clippingsNCT
Pharma Manufacturing: eXoZymes picks Curia as commercial-scale manufacturing partnerSeptember 14, 2026
PharmaSource podcast featuring EXOZ CCO, Perriman
investorpodcastperrimanNCT
PharmaSource podcast: How EXOZ Is Running a 10-CDMO RFP for CDMO SelectionSeptember 9, 2026
Dr. Paul Opgenorth from eXoZymes at Curia in Italy
investorperrimanNCT
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCTSeptember 8, 2026
WBMI: Scaling without Cells
investornutraceuticalspress clippingsperrimanNCT
World Bio Market Insights: Scaling without CellsSeptember 3, 2026
Inside eXoZymes’ Strategic Shift: Building a Compounding Value Flywheel
investorpress clippingsNCT
Slack Capital: Inside EXOZ’ strategic shift - building a compounding value flywheelAugust 27, 2026
WTR: EXOZ 2Q26 update - from platform validation to commercial execution
investorpress clippingsNCT
WTR: EXOZ 2Q26 update - from platform validation to commercial executionAugust 25, 2026
NCT process advances beyond original commercial-scale economic targets
press releaseinvestorscienceperrimanNCT
eXoZymes' NCT process achieves 10-fold productivity increase, advancing beyond original commercial-scale economic targetsAugust 18, 2026
Ladder17 podcast: How eXoZymes is Scaling as a Public Company
nutraceuticalspress clippingspodcastperrimanNCT
Ladder17 podcast: How eXoZymes is Scaling as a Public CompanyJune 25, 2026
Finding Genius: eXoZymes AI-Enhanced Enzymes & The Future Of Sustainable Manufacturing
press clippingssciencepodcastNCTcannabinoidskorman
Finding Genius podcast: AI enhanced enzymes & the future of sustainable manufacturingMay 12, 2026
WTR Healthcare Happenings
heltzennutraceuticalspress clippingspodcastNCT
WTR podcast: Unlocking Hard-to-Scale Molecules with AI-Driven, Cell-Free BiomanufacturingMay 6, 2026
Previous page
Page 1 of 3
Next page